Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Drug Product Performance: In Vitro–In Vivo Correlation01:20

Drug Product Performance: In Vitro–In Vivo Correlation

In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while adhering...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

LDL-cholesterol distance to target: A practical tool for guiding lipid-lowering treatment decisions.

Atherosclerosis plus·2026
Same author

Osmotic Remodeling of Extracellular Vesicles for Precision Nanomedicine.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

Corrigendum to "Heated tobacco product aerosol emission compared to cigarette smoke: A scoping review" [Toxicol. Rep. 16 (2026) 102209].

Toxicology reports·2026
Same author

Are we underestimating the benefits of lipid-lowering therapies?

Pharmacological reviews·2026
Same author

Hemostatic Aspects of Interactions Between Anticancer Drugs and Oral Anticoagulants in Patients with Cancer-Associated Venous Thromboembolism.

Seminars in thrombosis and hemostasis·2026
Same author

New frontiers in the treatment of hypercholesterolaemia: oral inhibition of PCSK9.

European heart journal supplements : journal of the European Society of Cardiology·2026
Same journal

Editorial introduction.

Current opinion in lipidology·2026
Same journal

Heterozygosity for pathogenic variants in familial chylomicronemia syndrome genes: from carrier state to complex trait.

Current opinion in lipidology·2026
Same journal

Premature atherosclerotic cardiovascular disease in the MENA region: economic impact, barriers to care, and policy recommendations for an escalating crisis.

Current opinion in lipidology·2026
Same journal

The role of metabolic profiling and dietary intervention in the early diagnosis and prevention of atherosclerosis.

Current opinion in lipidology·2026
Same journal

A JAK of two trades: beneficial or adverse effects of Janus kinase inhibition for plasma LDL-cholesterol and major adverse cardiovascular events in inflammatory bowel disease patients?

Current opinion in lipidology·2026
Same journal

Inflammation and atherosclerotic cardiovascular disease: where do we go from here?

Current opinion in lipidology·2026
See all related articles

Related Experiment Video

Updated: Jun 11, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Do structural differences in statins correlate with clinical efficacy?

Lorenzo Arnaboldi1, Alberto Corsini

  • 1Department of Pharmacological Sciences, Faculty of Pharmacy, Università degli Studi di Milano, Milan, Italy.

Current Opinion in Lipidology
|June 29, 2010
PubMed
Summary
This summary is machine-generated.

Statin drug structures influence their non-lipid effects, impacting cardiovascular health beyond cholesterol reduction. Tailoring statin therapy may offer personalized atherosclerosis control, especially for high-risk patients.

Related Experiment Videos

Last Updated: Jun 11, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Biochemistry

Background:

  • Statins inhibit HMG-CoA reductase, reducing cholesterol and mevalonate derivatives.
  • Non-lipid-lowering (pleiotropic) effects are linked to mevalonate derivatives.
  • Statin structure may influence both lipid-lowering and pleiotropic actions.

Purpose of the Study:

  • To review the correlation between statin chemical structures and their clinical effects.
  • To explore how structural differences contribute to statins' pleiotropic properties.
  • To assess the role of statin structure in acute versus chronic cardiovascular benefits.

Main Methods:

  • Literature review of clinical and ex-vivo studies.
  • Analysis of studies focusing on acute coronary syndrome patients.
  • Comparison of statin effects independent of LDL-C reduction.

Main Results:

  • Early statin treatment benefits in acute coronary syndrome may stem from pleiotropic effects.
  • Atorvastatin, but not simvastatin, inhibited smooth muscle cell proliferation in ex-vivo studies.
  • These effects were observed independently of low-density lipoprotein cholesterol (LDL-C) reduction.

Conclusions:

  • Statin structure is linked to anti-inflammatory and pleiotropic properties.
  • Tailored statin therapy, based on structure, could offer personalized atherosclerosis management.
  • This approach is particularly relevant for high-cardiovascular-risk individuals.